New research and interpretations: is low cholesterol really a health risk?

Editorial note: This article was previously published and has been updated according to scientific and informative criteria. The information reported here is for informational purposes only and does not replace the advice of your treating physician. For personal clinical decisions, always consult a healthcare professional.

IN BRIEF

• Epidemiological observations indicate that, in some contexts, very low blood cholesterol levels are associated with an increased risk of cerebral hemorrhage and, in some studies, with non-cardiovascular outcomes such as certain cancers or cognitive decline.
• Most evidence is observational: associations do not automatically imply causality. The possibility of "reverse causation" (preclinical disease reducing cholesterol) is documented.
• LDL cholesterol reduction with therapies (statins, PCSK9, etc.) clearly reduces the risk of ischemic events; the risk-benefit profile must be evaluated on a case-by-case basis according to overall cardiovascular risk.
• The biological role of cholesterol is complex: it is a structural component of cell membranes, a precursor to hormones, and involved in immune processes and tissue repair.

Abstract: what does science say?

Definition: Cholesterol is a lipid substance produced by the body and transported in the blood within lipoproteins (LDL, HDL). It is measured as total cholesterol, LDL, HDL, and triglycerides.

Evidence: Observational studies indicate inverse relationships between very low cholesterol levels and the risk of hemorrhagic stroke, certain types of cancer, and, in some cohorts, worse cognitive decline or faster progression of neurodegenerative diseases. At the same time, extensive experimental and clinical literature confirms that targeted LDL reduction reduces mortality and cardiovascular ischemic events.

Context dependence: The observed effects depend on the range of levels (very low vs. moderate), the population (age, comorbidities, use of lipid-lowering therapies), follow-up time, and the presence of pre-existing disease that can influence cholesterol levels.

Interpretive limitations: Most reports come from observational studies subject to confounding and reverse causation; reviews of randomized trials do not show convincing direct cognitive or oncological adverse effects of statins. Therefore, data must be interpreted with caution, and the individual risk/benefit ratio must be evaluated.

Main Section

Why some studies suggest risks with low cholesterol

Population studies have observed that very low levels of total cholesterol or LDL are associated with a higher incidence of intracerebral hemorrhage compared to higher levels; meta-analyses and prospective studies show an inverse association between LDL (or total cholesterol) and the risk of hemorrhagic stroke, maintained even after adjustment for various risk factors [1][2]. Several biological mechanisms are plausible: cholesterol is a component of the vascular wall and can contribute to its integrity, so very low levels could, in theory, make some vessels more vulnerable to rupture in predisposing contexts. However, the data are not uniform, and populations and methods vary widely: some more recent meta-analyses have quantified the dose-response relationship but have also highlighted the heterogeneity of the studies [3].

Cholesterol, memory, and neurodegenerative diseases

Associations between lipid profiles and cognitive functions have been described: in middle-aged cohorts, low HDL has been associated with a higher risk of memory decline over time [4]. Some observational studies have reported that higher cholesterol levels are linked to comparable or slightly slower progression in specific Parkinson's cohorts, while others have not confirmed the effect [10]. Overall, the literature suggests correlations but does not prove a clear causal link. Clinical trials that have examined the effects of statins on cognition do not show robust evidence to support substantial cognitive impairment associated with therapy; however, post-marketing reports and case reports indicate rare adverse reactions (e.g., irritability) that warrant clinical attention [8][7].

What it means in practice

For the reader: cholesterol is not simply "good" or "bad" in absolute terms. The primary clinical value of lipid control concerns the reduction of ischemic events (heart attack and ischemic stroke) when cardiovascular risk is high; for these people, lipid-lowering therapy (statins and other drugs) has shown clear benefits. At the same time, some observational signals indicate that very low levels of LDL/total cholesterol may be associated with specific risks (e.g., cerebral hemorrhage) in certain populations [1][2][3]. This does not mean that therapy is dangerous for everyone: modern guidelines evaluate the personalized risk/benefit balance and recommend differentiated targets based on overall risk. If you are undergoing treatment to lower cholesterol, the choice of target and drug should arise from a doctor-patient discussion that considers age, medical history, cardiovascular risk, and preferences. Do not stop therapies without consulting your doctor; if you notice new symptoms (changes in memory, mood, unusual bleeding), report them promptly.

Cholesterol helps fight infections

Cholesterol and its derived metabolites play roles in cellular metabolism and immune responses. Recent experimental studies show that some pathogens such as Mycobacterium tuberculosis interact with host cholesterol metabolism and can use or modify sterols to survive; specific metabolites produced during infection have been identified as markers and can modulate the inflammatory response [6]. These observations do not equate to "protective cholesterol" universally against infections but highlight the complexity of the relationship between lipids, immunity, and pathogens. Interventions that profoundly alter lipid metabolism may have immunometabolic effects that need to be evaluated in specific contexts.

Key takeaways

• Numerous observational studies show inverse associations between very low cholesterol levels and the risk of hemorrhagic stroke; the clinical significance depends on the individual context [1][2].
• Associations with cancer and non-cardiovascular mortality have been highlighted in historical and recent cohorts; reverse causation (preclinical disease lowering cholesterol) is an important alternative explanation [5].
• To reduce ischemic cardiovascular risk, targeted LDL reduction remains a strategy supported by clinical trials: the benefit is clear for many people at risk [8].
• Rare reports link statins to mood or memory disorders; the overall literature does not support a generalized severe cognitive effect, but clinical surveillance remains necessary [7][8].

Limitations of the evidence

The main distinction is between observational studies and causal evidence: observational data can show correlations but are subject to the risk of residual confounding and reverse causation. For example, low cholesterol levels measured shortly before a cancer diagnosis may be the (preclinical) result of the disease itself, not the cause [5]. Furthermore, methodological variability (non-fasting measurements, different thresholds, adjustment for confounding factors) complicates syntheses. Meta-analyses offer aggregated estimates but reflect the heterogeneity of individual research [1][3]. Randomized trials remain the gold standard for establishing therapeutic causality; many RCTs have shown that LDL reduction reduces ischemic events and cardiovascular mortality, while the effect on non-cardiovascular outcomes is less consistent. Finally, the role of the lipid fraction (LDL vs. HDL) and their biological function cannot be reduced to a single number: quality and context matter.

Editorial conclusion

The topic of "low cholesterol" is more nuanced than simplistic slogans suggest. Science shows signals where very low levels are associated with certain risks, particularly for hemorrhagic stroke and in specific observational conditions. However, the substantial body of evidence supporting the reduction of ischemic risk through targeted LDL lowering with lipid-lowering therapies remains solid. Clinical evaluation must be individual: the physician must consider the overall cardiovascular risk profile, personal history, potential benefits, and weak risk signals. For readers: maintain open dialogue with your doctor, do not stop therapies without advice, and report suspected adverse effects.

Editorial note

This article has been updated to include recent research and systematic reviews to improve rigor and transparency. The content is informative and does not replace personalized medical advice.

SCIENTIFIC RESEARCH

1. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke. 2013;44(7):1833–1839. https://doi.org/10.1161/STROKEAHA.113.001326 [1]
2. Low‑density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019;93(5):e445–e457. https://doi.org/10.1212/WNL.0000000000007853 [2]
3. Lipid levels and the risk of hemorrhagic stroke: A dose‑response meta‑analysis. Nutrition, Metabolism & Cardiovascular Diseases. 2020;30(1):xx‑xx. https://doi.org/10.1016/j.numecd.2020.10.014 [3]
4. Singh‑Manoux A, Gimeno D, Kivimäki M, et al. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol. 2008;28:1556–1562. https://doi.org/10.1161/ATVBAHA.108.163998 [4]
5. Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me‑Can). PLoS ONE. 2013;8(1):e54242. https://doi.org/10.1371/journal.pone.0054242 [5]
6. Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection. J Clin Invest. 2022;132:e152509. https://doi.org/10.1172/JCI152509 [6]
7. Severe irritability associated with statin cholesterol‑lowering drugs. QJM. 2004;97(7):403–405. https://doi.org/10.1093/qjmed/hch035 [7]
8. Do statins impair cognition? A systematic review and meta‑analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348–358. https://doi.org/10.1007/s11606-014-3115-3 [8]
9. Accelerated telomere attrition and its association with cholesterol: Shiels P, McGlynn KA, et al. PLoS ONE. 2011;6(7):e22521. https://doi.org/10.1371/journal.pone.0022521 [9]
10. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS ONE. 2011;6(8):e22854. https://doi.org/10.1371/journal.pone.0022854 [10]